The study also found that patients with a later best confirmed response to therapy demonstrated improved outcomes compared with patients who experienced an early best confirmed response. A secondary ...
Selinexor is the first selective inhibitor of nuclear export to be approved for the treatment of relapsed or refractory multiple myeloma (MM). Currently, there are no known genomic biomarkers or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback